Our founder presented the research behind Synthena at the Royal Society in London

The talk came eight months before the company was founded. This post records what was shown and what followed.

On 7 November 2025, before Synthena existed, our founder presented its research at the Royal Society in London. The event was Through the Oriental Glass, where twelve teams of young scientists showed their research.

He showed PDRN made from plant and microbial sources and held within a defined range between 20 and 80 base pairs. He showed the three steps that make it, which are extraction, purification and the step that brings the DNA to the defined range.

Since that day we have worked on the third step, so that it repeats batch after batch. Eight months after that day in London, in July 2026, we founded Synthena Pharmaceuticals to carry the work forward. The next update will follow when the next batch has been characterised.

We are studying the material in cardiology, dermatology, orthopaedics, gastroenterology and neurology. Dermatology is the most advanced programme and it is preclinical. The other four are in research. No programme has entered clinical trials, and no Synthena medicine has been approved for any indication.

Tien Phong published an article on the event on 11 November 2025.